Article
Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.
Journal for immunotherapy of cancer - 1 Jul 2022
Takamatsu Shiro, Hamanishi Junzo, Brown J B, Yamaguchi Ken, Yamanoi Koji, Murakami Kosuke, Gotoh Osamu, Mori Seiichi, Mandai Masaki, Matsumura Noriomi
Abstract excerpt
BACKGROUND: In cancer therapy, higher-resolution tumor-agnostic biomarkers that predict response to immune checkpoint inhibitor (ICI) therapy are needed. Mutation signatures reflect underlying oncogenic processes that can affect tumor immunogenicity, and thus potentially delineate ICI treatment response among tumor types. METHODS: Based on mutational signature analysis, we developed a stratification for all solid...
Topics
- Biomarkers, Tumor
- Genomics
- Humans
- Mutation
- Neoplasms
- Exome Sequencing